In­ven­ti­va stock sinks 20% af­ter se­ri­ous ad­verse event in NASH tri­al leads to en­roll­ment pause

Last year
R&D

Gilead stops re­cruit­ment in CD47 sol­id tu­mor tri­als, a week af­ter it axed blood can­cer de­vel­op­ment

Last year
R&D

Gri­fols fam­i­ly to step away fur­ther from op­er­a­tions; en­Gene CEO re­signs, cit­ing health rea­sons

Last year
People
Peer Review

Astel­las pur­sues ‘con­vert­ible’ in vi­vo CAR-T cell ther­a­pies with Kelo­nia Ther­a­peu­tics

Last year
Deals
Cell/Gene Tx

FDA goes af­ter web­sites mar­ket­ing 'u­nap­proved' semaglu­tide, tirzepatide

Last year
Pharma
FDA+

Es­hoo calls out FDA for miss­ing dead­line on di­ver­si­ty ac­tion plan guid­ance

Last year
Pharma
FDA+

GSK re­fresh­es ‘Shin­gles doesn’t care’ cam­paign with fo­cus on hard­er-to-reach groups

Last year
Pharma
Marketing

Marks re­hash­es Covid-19 ap­proval time­line, de­fends vac­cines for chil­dren at hear­ing

Last year
Pharma
FDA+

FDA com­mis­sion­er hints at car­dio-re­lat­ed la­bel ex­pan­sion for We­govy, full ap­proval for Lil­ly's new Alzheimer's drug

Last year
FDA+

No­vo-Catal­ent deal like­ly to be one-off — with some caveats, in­sid­ers say

Last year
Deals
Manufacturing

VBI sells vac­cine and fa­cil­i­ty for $33M; Bay­er gets ra­dioiso­topes from Pan­Tera; Ther­mo Fish­er’s PPD ex­pands ...

Last year
Manufacturing

Charles Riv­er’s CD­MO rev­enue rise; Catal­ent lays off 300 staffers; Bio­gen’s idle ca­pac­i­ty

Last year
Manufacturing

Up­dat­ed: Al­ny­lam de­lays high­ly-an­tic­i­pat­ed AT­TR read­out as it changes study de­sign

Last year
R&D

'Obe­si­ty plus': What’s next for GLP-1s?

Last year
R&D
In Focus

KalVista wants to raise $160M; Prime Med­i­cine's up­sized of­fer­ing; Ap­plied Tx's PhI­II da­ta

Last year
News Briefing

Ap­n­imed, a late-stage sleep ap­nea biotech, eyes IPO in the sec­ond half

Last year
Financing
Startups

Car­olyn Bertozzi and Ver­san­t's new biotech breaks cov­er with $94M to use pro­tein de­graders in AD­Cs

Last year
Financing
Startups

Au­rinia fails to find buy­er, will shed pipeline to fo­cus on Lup­ky­nis

Last year
People
R&D

GSK wins ap­peal to on­ly pay As­traZeneca roy­al­ties on some sales of can­cer drug Ze­ju­la

Last year
Law

Pfiz­er could end Lip­i­tor an­titrust saga in­volv­ing Ran­baxy with $93M set­tle­ment

Last year
Pharma
Law

Freenome rais­es $254M for ear­ly can­cer de­tec­tion tests

Last year
Financing
Diagnostics

Will slow up­take of Leqem­bi pose a risk to Bio­gen’s re­cov­ery?

Last year
Pharma

Eicos Sci­ences wins FDA ap­proval for first se­vere frost­bite treat­ment

Last year
Pharma
FDA+

Biden ad­min­is­tra­tion tar­gets GPOs, whole­salers in re­quest for in­for­ma­tion on gener­ic short­ages

Last year
Pharma
FDA+
First page Previous page 199200201202203204205 Next page Last page
A service from the Financial Times